Inducing, Understanding and Overcoming Resistance to Everolimus in Pancreatic Neuroendocrine Tumors

#977

Introduction: Treatment with the mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumors (PNETs). However, adaptive resistance to mTOR inhibition is described.

Aim(s):

Materials and methods: QGP-1 and BON-1, two human PNET cell lines, were cultured with increasing concentrations of everolimus during 20 to 22 weeks to reach a final dose of 1000-fold and 250-fold the initial IC50, respectively. BON cell lines with induced resistance were compared with the initial cell line using whole exome sequencing. The cell lines with induced everolimus resistance were treated with BEZ-235, a combined PI3K-mTOR inhibitor.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Vandamme T

Authors: Vandamme T, Op de Beeck K, Beyens M, Mortier G, Pauwels P,

Keywords: everolimus,

To read the full abstract, please log into your ENETS Member account.